Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

Clinical trial NCT06371482 · RECRUITING

Trial details

NCT number: NCT06371482
Sponsor: Hebei Medical University Fourth Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

SCLC, Limited Stage

Start date: 2023-06-01
Primary completion: 2024-12-31
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.